Single-Site, Open-Label, Randomized, Cross-Over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5mg/10cm2) From 2 Different Manufacturing Processes.

Trial Profile

Single-Site, Open-Label, Randomized, Cross-Over Trial to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (4.5mg/10cm2) From 2 Different Manufacturing Processes.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors UCB
  • Most Recent Events

    • 28 Apr 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top